Praised by his PhD students for his compassion, enthusiasm, and collaborative nature, University of Colorado Cancer Center member Edward Chuong, PhD, is one of 13 faculty members at CU Boulder to be recognized as an outstanding graduate student mentor for 2024.
Research Lung Cancer Awards Pulmonology
Asked if there’s a lesson for other medical researchers in his decades-long career, York Miller, MD, says it’s this: “If you see something promising, don’t be reluctant to change direction.”
University of Colorado Cancer Center member Rosemary Rochford, PhD, has spent the past 34 years researching the Epstein-Barr virus (EBV) a virus that causes several types of cancer, including Burkitt lymphoma, nasopharyngeal carcinoma, gastric carcinoma, Hodgkin’s disease, and non-Hodgkin’s lymphoma.
Research Funding Awards Cell and Gene Therapy
A project to develop a way to boost the effectiveness of cellular cancer therapies, led by the University of Colorado Cancer Center’s Associate Director of Cancer Research Training and Education Coordination, Eduardo Davila, PhD, is one of nine research endeavors by CU School of Medicine faculty members to be awarded major funding from the Anschutz Acceleration Initiative.
University of Colorado Cancer Center member Karolin Luger, PhD, a distinguished professor of biochemistry at CU Boulder, has been awarded the 2023 World Laureates Association (WLA) Prize in Life Science or Medicine.
University of Colorado Cancer Center member Ross Camidge, MD, PhD, has seen huge advances in lung cancer treatment during his years in the field.
The International Cytokine and Interferon Society has recognized University of Colorado Cancer Center member Edward Chuong, PhD, with its 2023 ICIS-Regeneron New Investigator Award for Excellence in Cytokine and Interferon Research.
For the past four years, University of Colorado Cancer Center member Sarah Tevis, MD, has focused her research on the psychosocial outcomes of breast surgery for women with breast cancer — specifically comparing patient-reported outcomes three and six months after receiving a lumpectomy (surgery in which just the tumor and some of the surrounding cells are removed) and a mastectomy (surgery to remove the entire breast).
The good news for people with multiple myeloma is that treatments exist that almost always put the cancer into deep remission soon after it’s diagnosed. The bad news for people with the blood cancer, though, is that even though that remission can last several years, almost all patients eventually relapse — and the disease that returns becomes increasingly difficult to treat.
Research Surgical Oncology Awards
For her innovative research on how cannabinoids affect the tumor immune microenvironment in melanoma, University of Colorado Cancer Center member Camille Stewart, MD, has been named to the 2023 cohort of the National Cancer Institute’s Early-Stage Surgeon Scientist Program (ESSP). The National Cancer Institute coordinates the United States National Cancer Program and is part of the National Institutes of Health (NIH).
Channing E. Tate, PhD, MPH, University of Colorado Cancer Center Rising Star, has seen through her personal and professional experiences how aging populations and communities of color often fall through the cracks of health care, especially at the end of life.
University of Colorado Cancer Center member Bryan Haugen, MD, always knew he was a science person. His question was if he wanted to be a MD or a PhD. After completing his bachelor’s degree at Saint Olaf College in Minnesota, he did a few years of research at the Mayo Clinic before starting medical school there.
Cure Today
July 12, 2024
University of Colorado Cancer Center member Dr. Steven Thorpe emphasizes the collaborative nature of treating soft tissue and bone sarcomas, highlighting the multidisciplinary efforts at CU School of Medicine's Department of Orthopedics and Children’s Hospital Colorado. He underscores the goal of not only curing the disease but also preserving function through advanced surgical techniques and modern therapies, ensuring patients maintain quality of life post-treatment. Thorpe stresses the importance of long-term outcomes, tailoring treatments to support patients’ aspirations beyond their cancer journey, especially for pediatric cases.
OncLive
July 08, 2024
CU Cancer Center member S. Lindsey Davis, MD, highlighted that the combination therapy of sapanisertib and alisertib showed marginal clinical benefit for patients with advanced solid tumors, correlative analyses suggested that apoptotic response and tumor immune cell infiltrate might influence clinical outcomes. The phase 1b study's expansion cohort indicated some positive outlying responses among patients and underscore the need for further research to tailor treatments for standout patients and explore rational combinations to enhance efficacy.
News Medical
June 19, 2024
A new study led by University of Colorado Cancer Center member Marco Del Chiaro, MD, PhD, reveals that nearly 5% of pancreatic adenocarcinoma patients achieved a pathological complete response (pCR) after pre-surgical chemotherapy or chemoradiotherapy. This significant finding indicates that patients with pCR have a 63% five-year survival rate, compared to 30% for those without pCR, suggesting the potential for tailored treatments to improve outcomes.
Cancer Network
June 14, 2024
In a conversation at the 2024 European Hematology Association Congress, CU Cancer Center member Manali Kamdar, MD, discussed potential future research on lisocabtagene maraleucel (liso-cel; Breyanzi) for mantle cell lymphoma (MCL) and other lymphoma subgroups. She highlighted findings from the phase 1 TRANSCEND NHL 001 trial, noting improved efficacy and safety in patients with fewer prior therapies and non-refractory disease, suggesting liso-cel's utility in earlier treatment lines and specific lymphoma subgroups.
Greg Glasgow
